Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | a small-molecule pocket: prexigebersen | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 5 Parkinson's papers of 3,678 | 0.76 |
| pathways Reactome | 97 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 6703
Sealed predictions
- GRB2 in dopamine neurons, braak-0.16 (p 0.682) → +0.40 (p 0.284)receipt 6711
Swarm cases
receipt 6711: GRB2 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.962, n 18), 95% CI -0.48 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.00 (p 0.990, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.02 (p 0.928, n 18). could be the mix.
- skeptic
- leave-one-out range -0.16 to +0.13, sign flips 6; without severely affected donors -0.01 (p 0.962, n 18). fragile.
- cell type
- strongest in OPCs: +0.60 (p 0.0086, n 18) vs -0.01 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GRB2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up GRB2 · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.70 p 0.013 (needs p < 3.1e-4)
Receipts
loading the receipts